Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned
ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the End of 2024 MELBOURNE, Australia...
Clinical Trial
Societal CDMO Announces Expansion of Controlled Substance Manufacturing Capabilities to Address Expanding Psychedelic Drug Development Market
Company Secures Schedule 1 Controlled Substance Manufacturing License from Drug Enforcement Agency, Expands on 25 Years of Manufacturing of Schedule...
EyePoint Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 2, 2023
WATERTOWN, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing...
Kincell Bio Launches with $36M to Make Cell Therapy Development and Manufacturing Accessible for Early-Stage Innovators
Cell therapy CDMO spins out of Inceptor Bio to help innovators develop and manufacture life-saving cell therapies Kincell to be...
PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023
PETACH TIKVA, Israel, July 26, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company...
AC Immune SA Appoints New Chief Medical Officer
AC Immune SA Appoints New Chief Medical Officer Nuno Mendonça, MD appointed new Chief Medical Officer and Executive Committee memberLausanne,...
Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023
HOUSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation...
Teleflex to Acquire Palette Life Sciences
Acquisition will add Barrigel®, a biodegradable sculptable rectal spacer, to Teleflex’s Interventional Urology portfolioWAYNE, Pa., July 26, 2023 (GLOBE NEWSWIRE)...
Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302
MELBOURNE, Australia, July 26, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies...
ALSA Ventures launches Vantage Biosciences to treat Diabetic Eye Disease
Diabetic eye diseases are the leading cause of blindness in the working age populationVX-01 is an oral therapy – current...
Cosmos Health Provides Update on Recent Developments, Maintains Strong Financial Position, Reaffirms Commitment to Growth, and Highlights CEO’s Continued Investment Now Exceeds $15 Million
CHICAGO, IL / ACCESSWIRE / July 25, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a global...
Napo Pharmaceuticals, a Jaguar Health Company, Supports Gay Men’s Health with Participation in Pineapple Healthcare’s “Butt Stuff Brunch with Dr. Carlton”
Napo Medical Affairs Team Member, who is an HIV/Mytesi® (Crofelemer) Patient, to Participate in Educational PanelSAN FRANCISCO, CA / ACCESSWIRE...
Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®
CINCINNATI, July 25, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology...
BaroPace Receives Approval for First-in-Human Clinical Trial
SAMMAMISH, Wash.--(BUSINESS WIRE)--BaroPace, Inc., a medical technology company dedicated to using blood pressure to regulate pacemakers for patients with heart...
MindBio Therapeutics Begins Recruitment of Participants for World First LSD-Microdosing Clinical Trial in Cancer Patients Experiencing Emotional Distress
World first take-home approvals for LSD-Microdosing in clinical trials in cancer patientsLSD-Microdosing combined with clinically proven Meaning Centred PsychotherapyVANCOUVER, BC...
US FDA Grants XVIVO Approval to Include DCD Hearts in IDE Clinical Trial
GOTHENBURG, SWEDEN / ACCESSWIRE / July 25, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) The US Food & Drug Administration (FDA)...
Medicure to Present Financial Results on July 31, 2023 Call at 8:30 AM ET for Quarter Ended June 30, 2023
WINNIPEG, MB / ACCESSWIRE / July 24, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused...
LENSAR® Reports Adoption of ALLY® System in Multi-Center Ophthalmology Groups
Private equity-owned ophthalmology group, EyeSouth Partners, adopts ALLY for each operating room within its Gainesville, Georgia and Boynton Beach, Florida...
The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch
Press release The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical...
BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
Initial topline data from COVALENT-101 trial revealed 2 complete responses (CRs) out of 5 relapsed/refractory AML patients carrying menin-dependent mutations...